Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.
about
Targeting survivin in cancer therapyDesign, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative PropertiesPaclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group.Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayRapamycin induces the anti-apoptotic protein survivin in neuroblastoma.Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancerDetection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 ExpressionMarkedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells.Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing.Potential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer.Recent Advances on Small-Molecule Survivin Inhibitors.Survivin as a preferential target for cancer therapy.Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.IRF5 promotes the proliferation of human thyroid cancer cells.R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant CancersAn executioner caspase regulates autophagy.Inhibitors of apoptosis: clinical implications in cancer.YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.Allicin activates autophagic cell death to alleviate the malignant development of thyroid cancer.
P2860
Q28273083-AFD4E028-B8A7-467D-ADFB-7F3D13877AC7Q28548275-CD6DD577-F49B-4CD4-8DF7-E23C1B0736C9Q33355378-E6A5A7A4-7432-4934-A0E7-C612E57D301DQ33691759-08FCDEC9-DE37-4B38-9857-6DB7F889C764Q33760761-CA88136E-20D6-46B8-9D17-5317127CF1DBQ34444867-68139786-198B-4576-8945-E33C276BCABCQ35887473-891AB3E8-60A5-4591-AB4C-772C04CB96D9Q36207331-A94B6958-7C9B-471A-B635-F5366EB1E392Q36343384-6423CBA8-3CD6-48A8-8F39-9071EF3A19B0Q36682843-ABEDA905-A195-42DC-B23C-6E1D7EFE129EQ36919815-E1440302-C8E2-4DEC-9C0E-64625A42FE80Q37112491-C8E53B3B-001F-461F-9186-D446510221AEQ37324196-54D09E57-AA69-4041-A4F2-E0A671572A3EQ37328494-769B93AB-68CC-4E87-83CC-407F5890B256Q37427435-FA5B1BF0-3495-4972-9FA9-9E240DEF9C81Q37467584-61CCC0AF-4A04-44B5-BF07-A9B1C0BCC79FQ37566689-041AB5CB-DD50-45D3-AF50-A4D0A1368A3FQ37657386-73F7A77F-5DF9-4BBA-8EB2-B1BE7B11F72EQ37689286-F0A5DBB1-A3F4-469F-9AD2-BFD532D90541Q38188377-55AB0210-33E1-43EE-B448-1CD482FD7297Q38388971-1C83C814-436F-4429-B118-4EBCD6A7E074Q38715683-68926818-46E0-4342-967E-63E2A6C81EB1Q38986068-C501CB34-32DC-427D-81EF-47475BC73121Q39364098-0DF8FEED-2C97-4AA3-9DC0-D3790DBCAF72Q39881718-3AC26BD6-7924-4F8E-89DD-6B0AF0E6D466Q39914343-A0815A7E-EAA9-4E9B-804E-A9C25ED708D3Q40314536-A33DFD39-2529-41A7-A36C-B6869A515B35Q40752477-056C0132-FC0F-49D6-8CD7-9AF6DAC14D8EQ42802552-F6D51CAE-C8A2-4F7D-9930-726126278A4EQ47607136-58956ECD-9185-49FC-A372-5C99E1283FAAQ49238703-EDC577B3-1194-4617-9249-C4E2B880AA1CQ53701719-1F332881-25B9-4FFE-B757-D7CB37D6A321
P2860
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Altered expression of c-IAP1, ...... tance in thyroid cancer cells.
@en
type
label
Altered expression of c-IAP1, ...... tance in thyroid cancer cells.
@en
prefLabel
Altered expression of c-IAP1, ...... tance in thyroid cancer cells.
@en
P2093
P50
P1433
P1476
Altered expression of c-IAP1, ...... stance in thyroid cancer cells
@en
P2093
Angelo Messina
Francesco Frasca
Giorgio Stassi
Luigi Messina
Luisa Vicari
Maria Letizia Consoli
Michele Massimino
P304
P356
10.1158/0008-5472.CAN-05-3248
P407
P577
2006-04-01T00:00:00Z